Publications
320 publications
Sort by: Date / Relevance
Conditional inclusion procedure for medicinal products
This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.
Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease
Zorginstituut Nederland has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult patients with ...
Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
Zorginstituut Nederland has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult patients with ...
GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
Zorginstituut Nederland has completed its assessment whether trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous ...
Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
Zorginstituut Nederland has completed its reassessment of the pharmaco-economic analysis of dabrafenib in combination with ...
International strategic agenda 2020 National Health Care Institute
When performing its tasks, the National Health Care Institute (Zorginstituut Nederland, or ZIN) participates with various other ...
Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Zorginstituut Nederland has completed its assessment whether oral semaglutide (Rybelsus®) is interchangeable with a product that ...
Specialist medicinal products assessment procedure
Zorginstituut Nederland only assesses specialist medicinal products that pose a risk to the accessibility, affordability or ...
Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
Zorginstituut Nederland has completed its assessment whether pentosan polysulfate sodium (Elmiron®) is interchangeable with a ...
12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
Zorginstituut Nederland has completed its assessment whether 12 SQ-HDM SLIT (Itulazax®) is interchangeable with a product that ...